Refrigerated Storage

MenopurFerring Pharmaceuticals Ltd

Ferring Pharmaceuticals Ltd
Powder and solvent for solution for injection (600 and 1200 units)

Contact Ferring Pharmaceuticals Ltd in all cases where a deviation from the recommended storage conditions has occurred. Refer to the current BNF for company contact details.
Please also refer to the manufacturer’s product literature for recommended storage information at

13 September 2021
London MI Service

New Medicines

Menopur Male and female infertility - pre-filled pen formulation


New formulation

Development and Regulatory status

Licensed but not launched
Approved (Licensed)
Phase III Clinical Trials
Jun 21Approved by MHRA for the treatment of female and male infertility [4].
Apr 21Approved in the EU [5].
Dec 20Also filed in the EU. Remains PIII in US [3].
Jul 20Currently pre-registration in UK. Two strengths of the solution for injection in a pre-filled pen have been filed (600iu and 1200iu) [2].


A gonadotrophin extracted from the urine of postmenopausal women. It has both luteinising hormone and follicle stimulating hormone activity in a 1:1 ratio.
It is estimated that infertility affects 1 in 7 heterosexual couples in the UK. Main causes of infertility in the UK are unexplained infertility (no identified male or female cause) (25%), ovulatory disorders (25%), tubal damage (20%), factors in the male causing infertility (30%) and uterine or peritoneal disorders (10%) [1].
Male and female infertility - pre-filled pen formulation
Subcutaneous injection